FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200048331> ?p ?o ?g. }

• W4200048331 endingPage "706" @default.
• W4200048331 startingPage "695" @default.
• W4200048331 abstract "In patients with atrial fibrillation (AF), peripheral artery disease (PAD) is associated with higher rates of stroke and bleeding. Both higher dose edoxaban (60/30 mg) and lower dose edoxaban (30/15 mg) were non-inferior to warfarin for stroke and systemic embolism (SSE) and significantly reduced major bleeding in AF patients in the global study to assess the safety and effectiveness of edoxaban vs standard practice of dosing with warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48) trial. Whether the efficacy and safety of these dosing strategies vs. warfarin are consistent in patients with AF and PAD has not been described.Of 21 105 patients with AF randomized to warfarin, edoxaban 60/30 mg, or edoxaban 30/15 mg, 841 were identified with PAD. Endpoints included major adverse cardiovascular events (MACEs), SSE, and major bleeding. Patients with PAD had higher risk of MACEs [adjusted hazard ratio (HRadj) 1.33, 95% confidence interval (CI) 1.12-1.57, P = 0.001] and cardiovascular (CV) death (HRadj 1.49, 95% CI 1.21-1.83, P < 0.001) than those without PAD, but not major bleeding. The efficacy of edoxaban 60/30 mg vs. warfarin was consistent regardless of PAD (SSE HR; PAD 1.16, 95% CI 0.42-3.20; no-PAD 0.86, 95% CI 0.74-1.02, P-interaction 0.57) as was major bleeding (PAD 0.96, 95% CI 0.54-1.70; no-PAD 0.80, 95% CI 0.70-0.91, P-interaction 0.54). Edoxaban 30/15 mg was inferior for SSE, with significant heterogeneity when stratified by PAD status (P-interaction 0.039).Patients with AF and PAD are at heightened risk of MACEs and CV death vs. those without PAD. The efficacy and safety of edoxaban 60/30 mg vs. warfarin in AF are consistent regardless of PAD; however, edoxaban 30/15 mg is inferior for stroke prevention in AF patients with PAD. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT00781391." @default.
• W4200048331 created "2021-12-31" @default.
• W4200048331 creator A5016322021 @default.
• W4200048331 creator A5019612250 @default.
• W4200048331 creator A5020677154 @default.
• W4200048331 creator A5020680320 @default.
• W4200048331 creator A5022267024 @default.
• W4200048331 creator A5072828160 @default.
• W4200048331 creator A5080846170 @default.
• W4200048331 creator A5082464840 @default.
• W4200048331 creator A5085897222 @default.
• W4200048331 creator A5086040903 @default.
• W4200048331 creator A5087033748 @default.
• W4200048331 creator A5090903599 @default.
• W4200048331 date "2021-12-28" @default.
• W4200048331 modified "2023-09-27" @default.
• W4200048331 title "Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48" @default.
• W4200048331 cites W1485191699 @default.
• W4200048331 cites W1586488555 @default.
• W4200048331 cites W1964424199 @default.
• W4200048331 cites W1965320794 @default.
• W4200048331 cites W2037500444 @default.
• W4200048331 cites W2096246254 @default.
• W4200048331 cites W2113645730 @default.
• W4200048331 cites W2147152303 @default.
• W4200048331 cites W2306365557 @default.
• W4200048331 cites W2572036822 @default.
• W4200048331 cites W2616330098 @default.
• W4200048331 cites W2768588165 @default.
• W4200048331 cites W2809811770 @default.
• W4200048331 cites W2913705661 @default.
• W4200048331 cites W2975859535 @default.
• W4200048331 cites W2989714602 @default.
• W4200048331 cites W2991282332 @default.
• W4200048331 cites W3013428853 @default.
• W4200048331 cites W3086493071 @default.
• W4200048331 cites W4229536675 @default.
• W4200048331 doi "https://doi.org/10.1093/ehjcvp/pvab089" @default.
• W4200048331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34962979" @default.
• W4200048331 hasPublicationYear "2021" @default.
• W4200048331 type Work @default.
• W4200048331 citedByCount "2" @default.
• W4200048331 countsByYear W42000483312023 @default.
• W4200048331 crossrefType "journal-article" @default.
• W4200048331 hasAuthorship W4200048331A5016322021 @default.
• W4200048331 hasAuthorship W4200048331A5019612250 @default.
• W4200048331 hasAuthorship W4200048331A5020677154 @default.
• W4200048331 hasAuthorship W4200048331A5020680320 @default.
• W4200048331 hasAuthorship W4200048331A5022267024 @default.
• W4200048331 hasAuthorship W4200048331A5072828160 @default.
• W4200048331 hasAuthorship W4200048331A5080846170 @default.
• W4200048331 hasAuthorship W4200048331A5082464840 @default.
• W4200048331 hasAuthorship W4200048331A5085897222 @default.
• W4200048331 hasAuthorship W4200048331A5086040903 @default.
• W4200048331 hasAuthorship W4200048331A5087033748 @default.
• W4200048331 hasAuthorship W4200048331A5090903599 @default.
• W4200048331 hasConcept C126322002 @default.
• W4200048331 hasConcept C127413603 @default.
• W4200048331 hasConcept C164705383 @default.
• W4200048331 hasConcept C207103383 @default.
• W4200048331 hasConcept C2776301958 @default.
• W4200048331 hasConcept C2777288759 @default.
• W4200048331 hasConcept C2777995511 @default.
• W4200048331 hasConcept C2778810321 @default.
• W4200048331 hasConcept C2779161974 @default.
• W4200048331 hasConcept C2780290652 @default.
• W4200048331 hasConcept C2780400711 @default.
• W4200048331 hasConcept C2780645631 @default.
• W4200048331 hasConcept C42219234 @default.
• W4200048331 hasConcept C44249647 @default.
• W4200048331 hasConcept C500558357 @default.
• W4200048331 hasConcept C71924100 @default.
• W4200048331 hasConcept C78519656 @default.
• W4200048331 hasConceptScore W4200048331C126322002 @default.
• W4200048331 hasConceptScore W4200048331C127413603 @default.
• W4200048331 hasConceptScore W4200048331C164705383 @default.
• W4200048331 hasConceptScore W4200048331C207103383 @default.
• W4200048331 hasConceptScore W4200048331C2776301958 @default.
• W4200048331 hasConceptScore W4200048331C2777288759 @default.
• W4200048331 hasConceptScore W4200048331C2777995511 @default.
• W4200048331 hasConceptScore W4200048331C2778810321 @default.
• W4200048331 hasConceptScore W4200048331C2779161974 @default.
• W4200048331 hasConceptScore W4200048331C2780290652 @default.
• W4200048331 hasConceptScore W4200048331C2780400711 @default.
• W4200048331 hasConceptScore W4200048331C2780645631 @default.
• W4200048331 hasConceptScore W4200048331C42219234 @default.
• W4200048331 hasConceptScore W4200048331C44249647 @default.
• W4200048331 hasConceptScore W4200048331C500558357 @default.
• W4200048331 hasConceptScore W4200048331C71924100 @default.
• W4200048331 hasConceptScore W4200048331C78519656 @default.
• W4200048331 hasIssue "7" @default.
• W4200048331 hasLocation W42000483311 @default.
• W4200048331 hasLocation W42000483312 @default.
• W4200048331 hasOpenAccess W4200048331 @default.
• W4200048331 hasPrimaryLocation W42000483311 @default.
• W4200048331 hasRelatedWork W1972269502 @default.
• W4200048331 hasRelatedWork W2174666533 @default.
• W4200048331 hasRelatedWork W2206334670 @default.

• next